The stock of BioVie Inc (BIVI) has gone down by -17.34% for the week, with a -28.48% drop in the past month and a -21.33% drop in the past quarter. The volatility ratio for the week is 6.91%, and the volatility levels for the past 30 days are 9.56% for BIVI. The simple moving average for the past 20 days is -20.66% for BIVI’s stock, with a -39.89% simple moving average for the past 200 days.
Is It Worth Investing in BioVie Inc (NASDAQ: BIVI) Right Now?
The 36-month beta value for BIVI is at 0.98. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BIVI is 15.36M, and currently, shorts hold a 11.97% of that float. The average trading volume for BIVI on December 17, 2024 was 5.98M shares.
BIVI) stock’s latest price update
BioVie Inc (NASDAQ: BIVI)’s stock price has gone decline by -10.18 in comparison to its previous close of 2.54, however, the company has experienced a -17.34% decrease in its stock price over the last five trading days. accesswire.com reported 2024-12-15 that NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. (“BioVie” or “the Company”) (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BIVI.
Analysts’ Opinion of BIVI
Many brokerage firms have already submitted their reports for BIVI stocks, with Cantor Fitzgerald repeating the rating for BIVI by listing it as a “Overweight.” The predicted price for BIVI in the upcoming period, according to Cantor Fitzgerald is $7 based on the research report published on July 22, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see BIVI reach a price target of $47. The rating they have provided for BIVI stocks is “Buy” according to the report published on January 15th, 2021.
BIVI Trading at -11.83% from the 50-Day Moving Average
After a stumble in the market that brought BIVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.11% of loss for the given period.
Volatility was left at 9.56%, however, over the last 30 days, the volatility rate increased by 6.91%, as shares sank -34.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +85.83% upper at present.
During the last 5 trading sessions, BIVI fell by -19.20%, which changed the moving average for the period of 200-days by -79.06% in comparison to the 20-day moving average, which settled at $2.87. In addition, BioVie Inc saw -81.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIVI
The total capital return value is set at -1.77. Equity return is now at value -236.52, with -113.61 for asset returns.
Based on BioVie Inc (BIVI), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -5.83. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -11.85.
Currently, EBITDA for the company is -31.95 million with net debt to EBITDA at 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In conclusion, BioVie Inc (BIVI) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
